Event-Driven Stocks

NOVAVAX INC

NVAXNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 3 warning● 3 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$1.12B$682.2M$983.7M$1.98B$1.15B$475.6M
Operating income$452.8M−$248.9M−$566.5M−$644.7M−$1.69B−$416.7M
Net income$440.3M−$187.5M−$545.1M−$657.9M−$1.74B−$418.3M
Total assets$1.18B$1.56B$1.80B$2.26B$2.58B$1.58B
Total liabilities$1.30B$2.18B$2.51B$2.89B$2.93B$955.3M
Equity−$127.8M−$623.8M−$716.9M−$634.1M−$351.7M$627.2M
EPS (diluted)$2.58$-1.23$-5.41$-8.42$-23.44$-7.27
Shares out.160.8M140.0M86.2M76.3M73.9M51.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
40.3%
Net margin
39.2%
Return on equity
−344.7%
Return on assets
37.4%
Return on capital (ROCE)
63.2%
Liabilities / assets
110.9%
Debt / equity
—
Book value / share
$-0.79
Revenue growth (YoY)
64.7%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-7.28distress
Accruals / assets
58.2%high accruals
Piotroski F-Score
6/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
54
/ 100
Profitability 80Growth 100Catalyst 67Earnings quality 0Financial strength 25

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 3 severe● 3 warning● 2 good
  • Negative shareholder equity
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Operating margin is positive
  • Revenue is growing year-over-year

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
1 acquisitions0 disposalsnet +9,520 shares · last 1
InsiderDateTypeSharesPrice
Newton Charles W.DirectorApr 25, 2026Option exercise9,520$0.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202645.3M6.3-8.5%
Apr 30, 202649.5M17.3+6.8%
Apr 15, 202646.3M15.0+3.0%
Mar 31, 202645.0M10.6-7.5%
Mar 13, 202648.6M11.3-4.5%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)